These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 25341706)

  • 1. Late stent thrombosis: can it be prevented?
    Mauri L; Galper BZ
    JACC Cardiovasc Interv; 2014 Oct; 7(10):1103-4. PubMed ID: 25341706
    [No Abstract]   [Full Text] [Related]  

  • 2. The complexity of stenting in bifurcation coronary lesions.
    Kornowski R
    JACC Cardiovasc Interv; 2013 Jul; 6(7):696-7. PubMed ID: 23866181
    [No Abstract]   [Full Text] [Related]  

  • 3. Very late stent thrombosis in everolimus-eluting stent with predisposing mechanical factors: Differential features.
    Jaguszewski MJ; Cortes C; Daucher H; Schincariol M; Halejcio M; Besuch P; Gutiérrez-Chico JL
    Cardiol J; 2017; 24(4):345-349. PubMed ID: 28831778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlates and outcomes of late and very late drug-eluting stent thrombosis: results from DESERT (International Drug-Eluting Stent Event Registry of Thrombosis).
    Waksman R; Kirtane AJ; Torguson R; Cohen DJ; Ryan T; Räber L; Applegate R; Waxman S; Gordon P; Kaneshige K; Leon MB;
    JACC Cardiovasc Interv; 2014 Oct; 7(10):1093-102. PubMed ID: 25240540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrent very late drug-eluting stent thrombosis.
    Duchini M; Fournier S; Iglesias JF; Roguelov C; Muller O; Eeckhout E
    Int J Cardiol; 2013 Oct; 168(4):e111-2. PubMed ID: 23988303
    [No Abstract]   [Full Text] [Related]  

  • 6. Neointimal erosion resulting in very-late stent thrombosis.
    Mori H; Sone H; Takei Y; Tashiro K; Sasai M; Maeda A; Sato T; Suzuki H
    Coron Artery Dis; 2019 Jun; 30(4):312-313. PubMed ID: 30694821
    [No Abstract]   [Full Text] [Related]  

  • 7. Evolving management of patients treated by drug-eluting stent: prevention of late events.
    Niccoli G; Sgueglia GA; Montone RA; Roberto M; Banning AP; Crea F
    Cardiovasc Revasc Med; 2014 Mar; 15(2):100-8. PubMed ID: 24603193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
    Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
    JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Late thrombosis after double versus single drug-eluting stent in the treatment of coronary bifurcations: a meta-analysis of randomized and observational Studies.
    Zimarino M; Corazzini A; Ricci F; Di Nicola M; De Caterina R
    JACC Cardiovasc Interv; 2013 Jul; 6(7):687-95. PubMed ID: 23769650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perioperative management of drug-eluting stents: the Achilles heel of bridging.
    Brilakis ES; Banerjee S
    Catheter Cardiovasc Interv; 2013 Dec; 82(7):1113-4. PubMed ID: 24255030
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of Durable-Polymer Zotarolimus-Eluting and Biodegradable-Polymer Biolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease: 3-Year Clinical Outcomes in the Randomized SORT OUT VI Trial.
    Raungaard B; Christiansen EH; Bøtker HE; Hansen HS; Ravkilde J; Thuesen L; Aarøe J; Villadsen AB; Terkelsen CJ; Krusell LR; Maeng M; Kristensen SD; Veien KT; Hansen KN; Junker A; Madsen M; Andersen SL; Jensen SE; Jensen LO;
    JACC Cardiovasc Interv; 2017 Feb; 10(3):255-264. PubMed ID: 28109874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing Stent Thrombosis associated with Zotarolimus Eluting Stents versus Everolimus Eluting Stents at 1 year follow up: a systematic review and meta-analysis of 6 randomized controlled trials.
    Bundhun PK; Yanamala CM; Huang WQ
    BMC Cardiovasc Disord; 2017 Mar; 17(1):84. PubMed ID: 28302055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stent failure due to simultaneous aggressive neoatherosclerosis of first- and current-generation drug-eluting stents.
    Komukai K; Bernelli C; Sirbu V; Guagliumi G
    EuroIntervention; 2015 Nov; 11(7):e1-2. PubMed ID: 26603864
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy of Endeavor zotarolimus-eluting stent implantation for the treatment of very late stent thrombosis with late-acquired incomplete stent apposition after sirolimus-eluting stent implantation.
    Kakefuda Y; Sato A; Watabe H; Aihara H; Nishina H; Noguchi Y; Hoshi T; Aonuma K
    Heart Vessels; 2016 Jul; 31(7):1196-9. PubMed ID: 26219730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of Vascular Imaging in Guiding Routine Percutaneous Coronary Interventions: A Meta-Analysis of Bare Metal Stent and Drug-Eluting Stent Trials.
    Alsidawi S; Effat M; Rahman S; Abdallah M; Leesar M
    Cardiovasc Ther; 2015 Dec; 33(6):360-6. PubMed ID: 26363283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coronary stent thrombosis in patients with chronic kidney disease: balancing anti-ischemic efficacy and hemorrhagic risk.
    Belardi JA; Albertal M
    Catheter Cardiovasc Interv; 2012 Sep; 80(3):368-9. PubMed ID: 22933347
    [No Abstract]   [Full Text] [Related]  

  • 17. Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients.
    Tada T; Byrne RA; Simunovic I; King LA; Cassese S; Joner M; Fusaro M; Schneider S; Schulz S; Ibrahim T; Ott I; Massberg S; Laugwitz KL; Kastrati A
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1267-74. PubMed ID: 24355117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kounis syndrome manifesting as coronary aneurysm and very late coronary stent thrombosis.
    Hoshi T; Sato A; Akiyama D; Kawabe M; Hiraya D; Aonuma K
    JACC Cardiovasc Interv; 2014 Nov; 7(11):e173-6. PubMed ID: 25459048
    [No Abstract]   [Full Text] [Related]  

  • 19. Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
    Gupta R; Kirtane AJ; Ozan MO; Witzenbichler B; Rinaldi MJ; Metzger DC; Weisz G; Stuckey TD; Brodie BR; Mehran R; Ben-Yehuda O; Stone GW
    Circ Cardiovasc Interv; 2017 Mar; 10(3):. PubMed ID: 28288963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
    Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.